We identified 2,898 commercially-insured men with events and recent testosterone use, and 339 from Medicare. Injected testosterone was associated with an increased risk of adverse events (composite outcome of myocardial infarction, stroke, or unstable angina) in the immediate post-injection period for the older, Medicare population only: commercial insurance, OR=0.98 (95% CI: 0.86-1.12); Medicare, OR=1.45 (1.07, 1.98). This association was either greatly attenuated or not present when evaluating receipt of any testosterone dosage forms (injection, gel, patch, implant): commercial insurance, OR=1.01 (0.92, 1.11); Medicare, OR=1.26 (95% CI: 0.98-1.63).
